Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cosentyx plus lifestyle intervention versus Cosentyx alone in adults with plaque psoriasis and metabolic syndrome
2016-001671-79Phase 4Completed
- Sponsor
- Novartis
- Start
- Nov 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of secukinumab in plaque psoriasis (2 arms), sponsored by Novartis. Primary endpoint: PASI90 at week 28. Started Nov 2017; status: completed.
02
Drugs
secukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2016-001671-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001671-79.